2016 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
11/23/16Navidea Signs Asset Purchase Agreement with Cardinal HealthDownload PDF
11/03/16Navidea Reports 2016 Third Quarter Financial ResultsDownload PDF
10/27/16Navidea Biopharmaceuticals to Announce Third Quarter 2016 Financial Results on November 3, 2016Download PDF
09/26/16Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive OfficerDownload PDF
09/22/16Navidea Achieves $1 Million in Lymphoseek® Commercial MilestonesDownload PDF
09/16/16Navidea’s Lymphoseek® Receives Positive Opinion in Europe for a New Reduced Mass VialDownload PDF
09/14/16Navidea to Present at Upcoming Investor ConferencesDownload PDF
09/06/16Navidea Biopharmaceuticals to Hold Investor Update CallDownload PDF
09/06/16Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of Lymphoseek® in North AmericaDownload PDF
08/11/16Navidea Biopharmaceuticals Announces 2016 Annual Meeting ResultsDownload PDF
08/08/16Navidea Executes a Term Sheet with Cerveau Technologies to Sublicense NAV4694Download PDF
08/04/16Navidea Reports Second Quarter 2016 Financial ResultsDownload PDF
07/28/16Navidea Biopharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016Download PDF
07/19/16Navidea Receives IRB Approval for its Lymphoseek® Rheumatoid Arthritis Clinical Trial ProtocolDownload PDF
06/16/16Navidea Announces Presentation of Results Demonstrating Performance of Lymphoseek® in Breast Cancer at SNMMIDownload PDF
06/14/16Navidea to Provide Shareholder UpdateDownload PDF
06/02/16Navidea Announces Data Presentations at 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)Download PDF
05/26/16$1.8 Million Fast-Track NIH SBIR Grant for Manocept™ Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to NavideaDownload PDF
05/23/16Navidea Provides Financing UpdateDownload PDF
05/17/16Navidea Reports First Quarter 2016 Financial ResultsDownload PDF
05/10/16Navidea Biopharmaceuticals to Announce First Quarter 2016 Financial Results on May 17, 2016Download PDF
05/03/16Navidea and Macrophage Therapeutics to Provide Development Program UpdateDownload PDF
04/26/16Navidea Appoints Jed Latkin as Interim Chief Operating OfficerDownload PDF
04/15/16Navidea and Macrophage Therapeutics to Provide Business UpdateDownload PDF
04/04/16Navidea Updates Clinical Development Plan for Diagnostic Use of Lymphoseek® IV in Rheumatoid ArthritisDownload PDF
03/23/16Navidea Announces Fourth Quarter and Full Year 2015 ResultsDownload PDF
03/21/16Navidea Biopharmaceuticals to Announce Fourth Quarter and Full Year 2015 Results on March 23, 2016Download PDF
03/14/16Navidea Biopharmaceuticals Announces Delay in Filing of Form 10-KDownload PDF
03/14/16Navidea and Platinum Enter Into Agreement Reaffirming Loan Obligations and Agreeing to Standstill ProvisionsDownload PDF
03/10/16Immunotherapeutic Potential of Manocept™ Platform Reviewed in the Journal Nuclear Medicine and BiologyDownload PDF
02/11/16Navidea Biopharmaceuticals Enrolls First Patient in Cervical Cancer Study of Lymphoseek®Download PDF
02/04/16Navidea Biopharmaceuticals to Present at 2016 BIO CEO & Investor ConferenceDownload PDF
02/02/16Navidea Provides Update on Lymphoseek® and Immunodiagnostics Development PipelineDownload PDF
01/11/16Navidea Meets Guidance With 2015 Unaudited Lymphoseek® Sales of $10.2 MillionDownload PDF
01/11/16Navidea Appoints Anton Gueth Chairman of the BoardDownload PDF
01/06/16Navidea Biopharmaceuticals Enrolls First Patient in Pediatric Trial of Lymphoseek®Download PDF
01/04/16Navidea Biopharmaceuticals to Present at Biotech Showcase 2016Download PDF